A Program to Reduce Post-Operative Opioid Prescribing at a Veteran’s Affairs Hospital
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Appendix A
Oxycodone 5 mg Tabs Used the Day Prior to Discharge b | Discharge Recommendation a (Oxycodone 5 mg Tabs, Tramadol 25 mg Tabs) |
---|---|
0 | None |
≤2 | 5 tabs oxycodone OR 8 tabs tramadol |
≤4 | 10 tabs oxycodone OR 15 tabs tramadol |
>4 | 15 tabs oxycodone OR 20 tabs tramadol |
Procedure | Discharge Recommendation a (Oxycodone 5 mg Tabs, Tramadol 25 mg tabs b) |
---|---|
Cholecystectomy | 5 tabs oxycodone OR 8 tabs tramadol |
Appendectomy | 5 tabs oxycodone OR 8 tabs tramadol |
Inguinal/umbilical hernia repair (open, laparoscopic, or robotic; bilateral or unilateral) | 5 tabs oxycodone OR 8 tabs tramadol |
Ventral hernia repair | 8 tabs oxycodone OR 12 tabs tramadol |
Hemorrhoidectomy | 5 tabs oxycodone OR 8 tabs tramadol |
Perirectal abscess I andD, fistulectomy, or seton placement | 5 tabs oxycodone OR 8 tabs tramadol |
Transanal excision | 5 tabs oxycodone OR 8 tabs tramadol |
Soft tissue excision (small area) | 0 tabs oxycodone/tramadol |
Procedure | Discharge Recommendation a (Oxycodone 5 mg Tabs, Tramadol 25 mg Tabs b) |
---|---|
Mediastinoscopy | 3 tabs oxycodone OR 5 tabs tramadol |
Pleural catheter placement | 3 tabs oxycodone OR 5 tabs tramadol |
Procedure | Discharge Recommendation a (Oxycodone 5 mg Tabs, Tramadol 25 mg Tabs b) |
---|---|
Endovascular procedures (i.e., angiography, angioplasty, stenting) | 2 tabs oxycodone OR 5 tabs tramadol |
Varicose vein therapy, (i.e., radiofrequency ablation, phlebectomy, vein ligation, vein stripping) | None |
Arteriovenous fistula creation/repair/ligation | 2 tabs oxycodone OR 5 tabs tramadol |
Arteriovenous graft creation/repair/ligation | 5 tabs oxycodone OR 8 tabs tramadol |
Toe amputation | 10 tabs oxycodone OR 15 tabs tramadol |
Appendix B
Item No | Recommendation | Page No | |
---|---|---|---|
Title and abstract | 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract | 1 |
(b) Provide in the abstract an informative and balanced summary of what was done and what was found | 1 | ||
Introduction | |||
Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 1 |
Objectives | 3 | State specific objectives, including any prespecified hypotheses | 2 |
Methods | |||
Study design | 4 | Present key elements of study design early in the paper | 2 |
Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 2 |
Participants | 6 | (a) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls | 2 |
(b) For matched studies, give matching criteria and the number of controls per case | 2 | ||
Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 2 |
Data sources/measurement | 8 | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 2 |
Bias | 9 | Describe any efforts to address potential sources of bias | 5 |
Study size | 10 | Explain how the study size was arrived at | 2 |
Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 2 |
Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | 2 |
(b) Describe any methods used to examine subgroups and interactions | n/a | ||
(c) Explain how missing data were addressed | n/a | ||
(d) If applicable, explain how matching of cases and controls was addressed | n/a | ||
(e) Describe any sensitivity analyses | n/a | ||
Results | |||
Participants | 13 | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | 3 |
(b) Give reasons for non-participation at each stage | n/a | ||
(c) Consider use of a flow diagram | n/a | ||
Descriptive data | 14 | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | n/a |
(b) Indicate number of participants with missing data for each variable of interest | n/a | ||
Outcome data | 15 | Report numbers in each exposure category, or summary measures of exposure | 3 |
Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 2–3 |
(b) Report category boundaries when continuous variables were categorized | 2–3 | ||
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | n/a | ||
Other analyses | 17 | Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses | n/a |
Discussion | |||
Key results | 18 | Summarise key results with reference to study objectives | 4 |
Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 5 |
Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 4–5 |
Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 5 |
Other information | |||
Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | n/a |
References
- Scholl, L.; Seth, P.; Kariisa, M.; Wilson, N.; Baldwin, G. Drug and Opioid-Involved Overdose Deaths—United States, 2013–2017. MMWR Morb. Mortal. Wkly Rep. 2019, 67, 1419–1427. [Google Scholar] [CrossRef] [PubMed]
- Roehler, D.R. Annual Surveillance Drug-Related Risks and Outcomes: United States, 2019. In 2019 Annual Surveillance Report of Drug-Related Risks and Outcomes—United States; CDC National Center for Injury Prevention and Control: Atlanta, GA, USA, 2019. [Google Scholar]
- Hedegaard, H.; Miniño, A.M.; Warner, M. Drug Overdose Deaths in the United States, 1999–2018; NCHS Data Brief, no 356; National Center for Health Statistics: Hyattsville, MD, USA, 2018.
- Makary, M.A.; Overton, H.N.; Wang, P. Overprescribing Is Major Contributor to Opioid Crisis. BMJ 2017, 359, j4792. [Google Scholar] [CrossRef] [PubMed]
- Hill, M.V.; McMahon, M.L.; Stucke, R.S.; Barth, R.J. Wide Variation and Excessive Dosage of Opioid Prescriptions for Common General Surgical Procedures. Ann. Surg. 2017, 265, 709–714. [Google Scholar] [CrossRef] [PubMed]
- Thiels, C.A.; Anderson, S.S.; Ubl, D.S.; Hanson, K.T.; Bergquist, W.J.; Gray, R.J.; Grazelka, H.M.; Cima, R.R.; Habermann, E.B. Wide Variation and Overprescription of Opioids After Elective Surgery. Ann. Surg. 2017, 266, 564–573. [Google Scholar] [CrossRef] [PubMed]
- Tan, W.H.; Yu, J.; Feaman, S.; McAllister, J.M.; Kahan, L.G.; Quasebarth, M.A.; Blatnik, J.A.; Eagon, J.C.; Awad, M.M.; Brunt, L.M. Opioid Medication Use in the Surgical Patient: An Assessment of Prescribing Patterns and Utilization. J. Am. Coll. Surg. 2018, 225, e91. [Google Scholar] [CrossRef] [PubMed]
- Nooromid, M.J.; Eddie, B.B.; Holl, J.L.; Bilimoria, K.Y.; Johnson, J.K.; Eskandari, M.K.; Stulberg, J.J. Discharge Prescription Patterns of Opioid and Nonopioid Analgesics after Common Surgical Procedures. Pain Rep. 2018, 3, e637. [Google Scholar] [CrossRef] [PubMed]
- Bicket, M.C.; Long, J.J.; Pronovost, P.J.; Alexander, G.C.; Wu, C.L. Prescription Opioid Analgesics Commonly Unused after Surgery: A Systematic Review. JAMA Surg. 2017, 152, 1066–1071. [Google Scholar] [CrossRef] [PubMed]
- Bates, C.; Laciak, R.; Southwick, A.; Bishoff, J. Overprescription of Postoperative Narcotics: A Look at Postoperative Pain Medication Delivery, Consumption and Disposal in Urological Practice. J. Urol. 2011, 185, 551–555. [Google Scholar] [CrossRef] [PubMed]
- Pommerening, M.J.; Landau, A.; Hrebinko, K.; Luketich, J.D.; Dhupar, R. An Analysis of Analgesia and Opioid Prescribing for Veterans after Thoracic Surgery. Sci. Rep. 2020, 10, 11348. [Google Scholar] [CrossRef] [PubMed]
- Chen, Q.; Hsia, H.L.; Overman, R.; Bryan, W.; Pepin, M.; Mariano, E.R.; Mudumbai, S.C.; Buchheit, T.; Krishnamoorthy, V.; Good, C.B.; et al. Impact of an Opioid Safety Initiative on Patients Undergoing Total Knee Arthroplasty: A Time Series Analysis. Anesthesiology 2019, 131, 369–380. [Google Scholar] [CrossRef] [PubMed]
- Benjamini, Y.; Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J. R. Stat. Soc. Ser. B Methodol. 1995, 57, 289–300. [Google Scholar] [CrossRef]
- Lee, J.S.; Howard, R.A.; Klueh, M.P.; Englesbe, M.J.; Waljee, J.F.; Brummett, C.M.; Sabel, M.S.; Dossett, L.A. The Impact of Education and Prescribing Guidelines on Opioid Prescribing for Breast and Melanoma Procedures. Ann. Surg. Oncol. 2019, 26, 17. [Google Scholar] [CrossRef] [PubMed]
- Starr, M.R.; Patel, S.V.; Bartley, G.B.; Bothun, E.D. Impact of Standardized Prescribing Guidelines on Postoperative Opioid Prescriptions after Ophthalmic Surgery. Ophthalmology 2020, 127, 1454–1459. [Google Scholar] [CrossRef] [PubMed]
- Illinois Surgical Quality Improvement Collaborative. Opioid Reduction Initiative. Available online: https://www.isqic.org/opioid-reduction-initiatives?lightbox=dataItem-jkbgrtn4 (accessed on 25 April 2022).
- Mayo Clinic Surgical Outcomes Program Recommendations for Adult Discharge Opioid Prescriptions. Available online: http://links.lww.com/SLA/B477 (accessed on 25 April 2022).
- Michigan Opioid Prescribing Engagement Network (OPEN). Opioid Prescribing Recommendations. Available online: https://michigan-open.org/prescribing-recommendations/ (accessed on 25 April 2022).
- Department of Public Health, City of Philadelphia. Postoperative Opioid Prescribing Guidelines. Available online: https://www.phila.gov/media/20181219135328/OpioidGuidelines-12_14.pdf (accessed on 7 September 2022).
- Vermont Department of Health. 2017 Rule Governing the Prescribing of Opioids for Pain. Available online: https://www.healthvermont.gov/sites/default/files/documents/pdf/BMP_Newsletter_Revised%20Opioid%20Rule%2008282017.pdf (accessed on 7 September 2022).
- Overton, H.N.; Hanna, M.N.; Bruhn, W.E.; Hutfless, S.; Bicket, M.C.; Makary, M.A.; Matlaga, B.; Johnson, C.; Sheffield, J.; Shechter, R.; et al. Opioid-Prescribing Guidelines for Common Surgical Procedures: An Expert Panel Consensus. J. Am. Coll. Surg. 2018, 227, 411–418. [Google Scholar] [CrossRef] [PubMed]
- Meisenberg, B.R.; Grover, J.; Campbell, C.; Korpon, D. Assessment of Opioid Prescribing Practices Before and After Implementation of a Health System Intervention to Reduce Opioid Overprescribing. JAMA Netw. Open 2018, 1, e182908. [Google Scholar] [CrossRef] [PubMed]
- Thiels, C.A.; Ubl, D.S.; Yost, K.J.; Dowdy, S.C.; Mabry, T.M.; Gazelka, H.M.; Cima, R.R.; Habermann, E.B. Results of a Prospective, Multicenter Initiative Aimed at Developing Opioid-Prescribing Guidelines After Surgery. Ann. Surg. 2018, 268, 457–468. [Google Scholar] [CrossRef] [PubMed]
- Hill, M.V.; Stucke, R.S.; Billmeier, S.E.; Kelly, J.L.; Barth, R.J. Guideline for Discharge Opioid Prescriptions after Inpatient General Surgical Procedures. J. Am. Coll. Surg. 2018, 226, 996–1003. [Google Scholar] [CrossRef] [PubMed]
Pre-Guidelines Mean | 95% CI | Post-Guidelines Mean | 95% CI | p-Value | Adj p-Value * | |
---|---|---|---|---|---|---|
Associated with guidelines | ||||||
Laparoscopic cholecystectomy (pre: N = 9; post: N = 10) | ||||||
Quantity | 18.8 | 15.03–23.5 | 8 | 6.12–10.5 | <0.001 | 0.002 |
# of days | 5.11 | 3.83–6.82 | 2.8 | 1.93–4.06 | 0.012 | 0.021 |
MME | 140.8 | 110.6–179.4 | 57.5 | 45.3–72.9 | <0.001 | 0.002 |
Inguinal hernia repair (pre: N = 25; post: N = 23) | ||||||
Quantity | 17.32 | 15.8–19.03 | 6.13 | 5.2–7.23 | <0.001 | 0.002 |
# of days | 5 | 4.20–5.96 | 2.43 | 1.87–3.16 | <0.001 | 0.002 |
MME | 129.9 | 118.4–142.5 | 45.3 | 40.7–50.5 | <0.001 | 0.002 |
Umbilical hernia repair (pre: N = 12; post: N = 6) | ||||||
Quantity | 17.17 | 14.66–20.1 | 7.83 | 5.76–10.6 | <0.001 | 0.002 |
# of days | 5.08 | 3.96–6.53 | 2.5 | 1.51–4.15 | 0.014 | 0.022 |
MME | 128.8 | 106.2–156.1 | 53.8 | 40.4–71.5 | <0.001 | 0.002 |
VATS (pre: N = 8; post: N = 5) | ||||||
Quantity | 18.8 | 13.19–26.6 | 10 | 6.17–16.2 | 0.039 | 0.052 |
# of days | 5.25 | 3.78–7.29 | 3.4 | 2.06–5.62 | 0.16 | 0.19 |
MME | 113.4 | 85.2–151.1 | 67.5 | 46.7–97.6 | 0.03 | 0.045 |
Not associated with guidelines | ||||||
CABG (pre: N = 20; post: N = 14) | ||||||
Quantity | 38.2 | 35.1–41.6 | 35.4 | 31.9–39.3 | 0.28 | 0.31 |
# of days | 9.55 | 8.01–11.4 | 12.64 | 10.43–15.3 | 0.035 | 0.049 |
MME | 286 | 261–314 | 266 | 238–297 | 0.3 | 0.313 |
Laminectomy (pre: N = 15; post: N = 14) | ||||||
Quantity | 70.7 | 53.7–93.0 | 28 | 15.2–51.7 | 0.001 | 0.002 |
# of days | 22.93 | 18.62–28.3 | 9.86 | 7.68–12.7 | <0.001 | 0.002 |
MME | 530 | 404–696 | 266 | 200–353 | 0.001 | 0.002 |
Kidney transplant (pre: N = 12; post: N = 5) | ||||||
Quantity | 47.1 | 31.9–69.5 | 28 | 15.2–51.7 | 0.16 | 0.19 |
# of days | 12.1 | 9.51–15.4 | 8.8 | 5.89–13.2 | 0.18 | 0.21 |
MME | 212 | 170–263 | 210 | 150–294 | 0.97 | 0.97 |
Carpal tunnel release (pre: N = 48; post: N = 41) | ||||||
Quantity | 21 | 19.2–23.0 | 16.5 | 14.8–18.3 | 0.001 | 0.002 |
# of days | 6.67 | 5.59–7.95 | 4 | 3.23–4.95 | <0.001 | 0.002 |
MME | 155 | 140–172 | 122 | 109–137 | 0.002 | 0.0037 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hlavin, C.; Muluk, S.; Muluk, V.; Ryan, J.; Wagner, J.; Dhupar, R. A Program to Reduce Post-Operative Opioid Prescribing at a Veteran’s Affairs Hospital. J. Clin. Med. 2022, 11, 5453. https://doi.org/10.3390/jcm11185453
Hlavin C, Muluk S, Muluk V, Ryan J, Wagner J, Dhupar R. A Program to Reduce Post-Operative Opioid Prescribing at a Veteran’s Affairs Hospital. Journal of Clinical Medicine. 2022; 11(18):5453. https://doi.org/10.3390/jcm11185453
Chicago/Turabian StyleHlavin, Callie, Sruthi Muluk, Visala Muluk, John Ryan, Jeffrey Wagner, and Rajeev Dhupar. 2022. "A Program to Reduce Post-Operative Opioid Prescribing at a Veteran’s Affairs Hospital" Journal of Clinical Medicine 11, no. 18: 5453. https://doi.org/10.3390/jcm11185453
APA StyleHlavin, C., Muluk, S., Muluk, V., Ryan, J., Wagner, J., & Dhupar, R. (2022). A Program to Reduce Post-Operative Opioid Prescribing at a Veteran’s Affairs Hospital. Journal of Clinical Medicine, 11(18), 5453. https://doi.org/10.3390/jcm11185453